Starlix (nateglinide), a new oral tablet for type 2 diabetes

April 2002

Novartis is now marketing Starlix (nateglinide), a new oral tablet for type 2 diabetes.

Think of it as a shorter-acting GlucoNorm (repaglinide).

Both meds are taken before meals to stimulate insulin release...but Starlix has a shorter duration.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

allow pharmacists to provide emergency contraceptive pills
Diabetes Starlix (nateglinide), a new oral tablet for type 2 diabetes
Diabetes metformin can lower vitamin B12 levels
Diabetes confused about the "sugar-free" candies marketed to patients with diabetes
Men's Health Xatral (ZAY-trall, alfuzosin), a new once-daily drug for benign prostatic hyperplasia
Women's Health new vaginal estrogen tablet called Vagifem
Women's Health latest thinking on treating osteoporosis in postmenopausal women
Infectious Diseases Lymerix is off the market
Cardiology New Canadian hypertension guidelines
Cardiology More patients will be taking Plavix (clopidogrel)
Multiple Sclerosis the different interferons for MS
Obesity & Weight Loss new concerns about the safety of Meridia (sibutramine)
Obesity & Weight Loss natural weight loss products
"nocebo effect"
Alzheimer's Disease link between homocysteine levels and dementia